Supplementary Methods

Protein production
The expression vectors pLMK550 and pLMK619 were transformed into Escherichia coli BL21* (DE3) pLysS (Invitrogen, Carlsbad, CA, cat. no. C6010-03). The protein production was induced at an OD 600 of 0.6 by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, Carl Roth, Karlsruhe, Germany, cat. no. CN08.3) to a final concentration of 0.5 mM.
After 2 hours at 37 °C, the cells were harvested by centrifugation at 6000 x g for 5 min at 4 °C, resuspended in lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0) and disrupted using a French press (APV, Albertslund, Denmark, model APV-2000). Cell debris were removed by centrifugation at 30000 x g for 20 min at 4 °C and the cell lysate was loaded onto a Ni 2+-NTA Superflow column (Qiagen, Hilden, Germany, cat. no. 30210). The column was washed twice with 20 ml wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0), after which the protein was eluted in 10 ml of elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole, pH 8.0). Additionally, for the VEGF SWITCH , the buffer was changed to 0.1 M Tris-HCl (pH 8), the protein was concentrated to 10 mg ml -1 by ultracentrifugation (10 kDa MWCO, Corning, Lowell, MA, cat. no. 431483), and the free cysteines were alkylated. For alkylation 0.16 mmol iodacetamide (IAA, Acros, Geel, Belgium, cat. no. 122270060) per mg of protein were added, after which the sample was flushed with argon for 30 s and incubated for 1 hour in the dark at room temperature. Finally, for both proteins, the buffer was changed to 50 mM Tris-HCl (pH 7.6) by ultracentrifugation.
The VEGF GyrB protein was shock frozen in liquid nitrogen immediately after the medium exchange and stored at -80 °C for later use, whereas VEGF SWITCH was subjected to size exclusion chromatography prior to freezing. VEGF 1, 2 as well as Gyrase B 3 were produced as described previously and stored at -80 °C. 
Size exclusion chromatography
The monomeric fraction of the VEGF SWITCH was isolated by size exclusion chromatography using an ÄKTAprime plus (GE Healthcare, Freiburg, Germany) fast liquid chromatography system with a HiLoad 16/60 Superdex 200 column (GE Healthcare, Freiburg, Germany, cat.
no. 17-1069-01) equilibrated with 50 mM Tris-HCl (pH 7.6). Size exclusion was carried out at 4 °C with a flow rate of 1 ml min -1 and a fraction volume of 2.5 ml. The monomeric fraction of VEGF SWITCH was eluted at 77.5-80 ml, which corresponds to a molecular weight of 44-54 kDa. The molecular weight profile was determined using a gel filtration standard (BioRad, Hercules, CA, cat. no. 151-1901). The isolated protein fraction was resolved by SDS-PAGE (12%, w/v) under non-reducing conditions and quantified via VEGF ELISA. The protein was shock frozen in liquid nitrogen and stored at -80 °C.
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